It's Your Business has Bill Persinger, Pamela Johnson Betts, Jennifer Goetz, Vince Frye
Judge Rebecca A. Sanders, chair of the Workers Compensation Appeals Board of the Kansas Department of Labor, Topeka, is the ...
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from ...
MyChesCo on MSN6d
Larimar Therapeutics Advances Friedreich's Ataxia Treatment After FDA Lifts Hold
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration ...
FierceBiotech7d
Larimar's Friedreich's ataxia program free at last from FDA hold
Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...
Larimar Therapeutics Says FDA Lifted Partial Clinical Hold For Nomlabofusp In Friedreich's Ataxia
(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...
Larimar Therapeutics Shares Up 22%, FDA Lifts Hold for Nervous System Disorder Treatment
Shares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration has lifted a partial clinical hold on the nomlabofusp program in ...
TMCnet7d
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar ...
Action News Now9d
Chico bike riders raise $5,000 for rare degenerative disease
The answers he got after over a year of searching, is that his condition would slowly take away his ability to walk, ride a ...
The UBJ on MSN13d
Discovery of Genetic Origin for Spinocerebellar Ataxia Type 4 Advances Research
Spinocerebellar ataxia type 4 (SCA4), while not widely known due to its rarity, has been a subject of intense investigation.
BMJ22d
Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion
upmc.fr Objective Spinocerebellar ataxia 36 (SCA36) is an autosomal-dominant neurodegenerative disorder caused by a large (>650) hexanucleotide GGCCTG repeat expansion in the first intron of the NOP56 ...